Fabry's disease - An important risk factor for stroke

Lancet

Volumn 366, Issue 9499, 2005, Pages 1754-1756

  Schiffmann, Raphael ^a   Ries, Markus ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROSIS; DIAGNOSTIC ACCURACY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; HEART DISEASE; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; NOTE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 27844441232     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67636-2     Document Type: Note

References (17)

1. A Rolfs, T Böttcher, M Zschiesche Prevalence of Fabry disease in young patients with cryptogenic stroke: a prospective study Lancet 366 2005 1794 1796
2. B Sachdev, T Takenaka, H Teraguchi Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy Circulation 105 2002 1407 1411
3. P Kotanko, R Kramar, D Devrnja Results of a nationwide screening for Anderson-Fabry disease among dialysis patients J Am Soc Nephrol 15 2004 1323 1339
4. S Nakao, C Kodama, T Takenaka Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype Kidney Int 64 2003 801 807
5. GE Linthorst, CEM Hollak, JC Korevaar, JG Van Manen, JM Aerts, EW Boeschoten α-galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease Nephrol Dial Transplant 18 2003 1581 1584
6. OY Bang, PH Lee, SY Joo, JS Lee, IS Joo, K Huh Frequency and mechanisms of stroke recurrence after cryptogenic stroke Ann Neurol 54 2003 227 234
7. RL Sacco, JH Ellenberg, JP Mohr Infarcts of undetermined cause: the NINCDS Stroke Data Bank Ann Neurol 25 1989 382 390
8. DF Moore, F Ye, ML Brennan Ascorbate decreases Fabry cerebral hyperperfusion suggesting a reactive oxygen species abnormality: an arterial spin tagging study J Magn Reson Imaging 20 2004 674 683
9. PF Bodary, Y Shen, FB Vargas α-galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency Circulation 111 2005 629 632
10. DF Moore, LT Scott, MT Gladwin Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy Circulation 104 2001 1506 1512
11. DF Moore, F Ye, R Schiffmann, JA Butman Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease AJNR Am J Neuroradiol 24 2003 1096 1101
12. MJ Hilz, EH Kolodny, M Brys, B Stemper, T Haendl, H Marthol Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease J Neurol 251 2004 564 570
13. G Altarescu, DF Moore, R Pursley Enhanced endothelium-dependent vasodilation in Fabry disease Stroke 32 2001 1559 1562
14. G Altarescu, DF Moore, R Schiffmann Effect of genetic modifiers on cerebral lesions in Fabry disease Neurology 64 2005 2148 2150
15. R Schiffmann, MK Floeter, JM Dambrosia Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease Muscle Nerve 28 2003 703 710
16. WR Wilcox, M Banikazemi, N Guffon Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Am J Hum Genet 75 2004 65 74
17. DF Moore, G Altarescu, GS Ling Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement Stroke 33 2002 525 531